NIH R01 · 2025
Targeting Lung Fibrosis Using Epigenetic Therapy
PROJECT SUMMARY Pulmonary fibrosis is a complex disease that limits lung function through development of collagen-rich scar tissue. Although there are currently two FDA-approved therapies for fibrosis patients, these drugs are capable of extending life only months and do not reverse the progression of the disease. The research described in this proposal would build upon evidence that reprogramming cellular fate through modulation of the epigenetic enzyme EZH2 can ameliorate several phenotypes of pulmonary fibrosis, including aberrant alveolar cell fate and pro-fibrotic cytokine signaling. Specifically, the aims will test if the FDA-approved EZH2 inhibitor, tazemetostat, will allow for…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.